翻訳と辞書 |
AZD3293
AZD3293, also known as LY3314814 is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. A BACE inhibitor in theory would prevent the build up of beta-amyloid and may help slow or stop Alzheimer's disease. In September 2014 AstraZeneca and Eli Lilly and Company announced an agreement to codevelop AZD3293. A pivotal Phase II/III clinical trial of AZD3293 started in late 2014 and is planned to recruit 1,500 patients and end in May 2019.〔(【引用サイトリンク】title=AstraZeneca and Lilly move Alzheimer's drug into big trial )〕 == References ==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「AZD3293」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|